FasterCures features a Q&A with Debra Miller, founder and CEO of CureDuchenne, in their Innovator Spotlight. FasterCures, a center of the Milken Institute, is an action tank driven by a singular goal – to save lives by speeding up and improving the medical research system.
The Q&A highlights CureDuchenne’s successful venture philanthropy model. It focuses on what prompted the creation of CureDuchenne to CureDuchenne’s research and development strategies and the organizations accomplishments including three projects CureDuchenne funded – Prosensa Holdings, Sarepta Therapeutics and PTC Therapeutics – that are the closest to being the first drugs to be approved for the treatment of Duchenne.
Click here to review the article.